



# **TB Vaccines**

**A Second Global Forum**

**David M. Lewinsohn, MD, PhD**  
Oregon Health and Sciences University

David M. Lewinsohn is Associate Professor of Medicine and Adjunct Associate Professor of Molecular Microbiology & Immunology at Oregon Health and Sciences University, and the Portland VA Medical Center. Dr. Lewinsohn received his undergraduate degree from Haverford College, his MD and PhD from Stanford University School of Medicine, internal medicine training at the University of California, San Francisco, and fellowship training in Pulmonary and Critical Care Medicine at the University of Washington.

Dr. Lewinsohn's research interest is in Tuberculosis Immunology. He is particularly interested in the role of CD8<sup>+</sup> T cells in controlling infection and in development of an improved TB vaccine. Specifically, he has worked to define of Mycobacterium tuberculosis-specific CD8<sup>+</sup> T cell that are restricted by both classical MHC molecules as well as the monomorphic MHC molecules HLA-E and MR1. Dr Lewinsohn has had a longstanding interest in the immunodiagnoses of infection with Mtb. In this capacity, he has collaborated with the CDC in the area of T cell diagnostic studies of tuberculosis in the setting of household exposure to Mtb, and is evaluating the diagnostic potential of CD8 antigens in Kampala, Uganda in collaboration with the TB Research Unit (TBRU). Dr. Lewinsohn is the co-chair of the ATS/CDC/IDSA committee to develop new guidelines for the diagnosis of infection with Mtb. Dr. Lewinsohn's research has been supported by the ALA, the NIH, the VA, and the Aeras Global Vaccine Foundation. His is also the recipient of an NIH Bioterrorism contract to comprehensively define human CD8 antigens and epitopes in Mycobacterium tuberculosis.